30 related articles for article (PubMed ID: 33308378)
21. Antitumor Activity of Lipid-DNA Aptamer Modified T Lymphocytes in Carcinoma.
Zhong L; Gan L; Deng Z; Liu X; Peng H; Tang H; Liu X; Fang F; Yao F; Li W; Liu Z; Hou W; Cui C; Zhao Y; Tan W; Shi W; He J
J Biomed Nanotechnol; 2020 Jul; 16(7):1110-1118. PubMed ID: 33308378
[TBL] [Abstract][Full Text] [Related]
22. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
Li Q; Maier SH; Li P; Peterhansl J; Belka C; Mayerle J; Mahajan UM
Radiat Oncol; 2020 Aug; 15(1):189. PubMed ID: 32758252
[TBL] [Abstract][Full Text] [Related]
23. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
24. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
25. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
27.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
28.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
29.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
